<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000700.v1.p1" parentStudy="phs000700.v1.p1" createDate="2014-01-07" modDate="2014-01-07">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Bradley Bernstein, MD, PhD</td><td>Massachusetts General Hospital, Boston, MA, USA, Broad Institute, Cambridge, MA, USA</td></tr>
		<tr><td>Principal Investigator</td><td>Alex Meissner, PhD</td><td>Harvard University Department of Stem Cell and Regenerative Biology, Cambridge, MA, USA, Broad Institute, Cambridge, MA, USA.</td></tr>
		<tr><td>Funding Source</td><td>Production Sequencing of Reference Human Epigenomes (U01 ES017155)</td><td>National Institutes of Health, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>RoadmapEpigenomics_Broad</StudyNameEntrez>
	<StudyNameReportPage>NIH Roadmap Epigenomics Program - Broad Institute</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Epigenetics</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>For the NIH Roadmap Epigenomics project, we applied ChlP-Seq, HTBS and WGBS pipelines to generate comprehensive high-resolution maps of chromatin state and DNA methylation for 100 diverse cell types. Cell types were selected for their biological and medical importance, and for their potential to maximize the comprehensiveness of acquired epigenomic data. They include human ES cells, ES-derived cells, mesenchymal stem cells, reprogrammed stem cells and primary tissues. Comprehensive characterization of epigenetic marks ("the epigenome") is a critical step towards a global understanding of the human genome in health and disease. In this study we provide unprecedented views of the human epigenetic landscape and its variation across cell states, which offer fundamental insight into the functions and interrelationships of epigenetic marks, and provide a framework for future studies of normal and diseased epigenomes.</p> <p><b>The Roadmap Epigenomics Broad cohort is utilized in the following dbGaP sub-study.</b> To view molecular data and derived variables collected in this sub-study, please click on the following sub-study below or in the "Sub-studies" box located on the right hand side of this top-level study page <a href="study.cgi?study_id=phs000700">phs000700</a> the Roadmap Epigenomics Broad cohort. <ul> <li><a href="study.cgi?study_id=phs000610">phs000610</a> RM_Epigenomics_Broad_Alz</li> </ul> </p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Inclusion by the Roadmap Epigenomics Program was limited to tissue samples judged as normal following pathology examination.</p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="23925113"/>
		</Publication>
		<Publication>
			<Pubmed pmid="20944595"/>
		</Publication>
		<Publication>
			<Pubmed pmid="23707066"/>
		</Publication>
		<Publication>
			<Pubmed pmid="23664763"/>
		</Publication>
		<Publication>
			<Pubmed pmid="23333102"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Nervous System Diseases"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Bradley Bernstein, MD, PhD</AttName>
			<Institution>Massachusetts General Hospital, Boston, MA, USA, Broad Institute, Cambridge, MA, USA</Institution>
		</Header>
		<Header title="Principal Investigator">
			<AttName>Alex Meissner, PhD</AttName>
			<Institution>Harvard University Department of Stem Cell and Regenerative Biology, Cambridge, MA, USA, Broad Institute, Cambridge, MA, USA.</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>Production Sequencing of Reference Human Epigenomes (U01 ES017155)</AttName>
			<Institution>National Institutes of Health, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="2" shortName="AARC" longName="Alzheimer&#39;s and age related conditions"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NIDA</DacName>
      <DacFullName>NIDA</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000700.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>9</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000700.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000700.v1.p1" FileName="DUC_for_REMC_Broad_Rush.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Alzheimer''s and age related conditions</ConsentName>
        <ConsentAbbrev>AARC</ConsentAbbrev>
        <UseLimitation>Consented to research in support of studies aimed at understanding the causes of Alzheimer&amp;#x2019;s disease and other age-related conditions.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
